These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 16551767)

  • 1. Advances in human immunodeficiency virus therapeutics.
    Clay PG; Dong BJ; Sorensen SJ; Tseng A; Romanelli F; Antoniou T
    Ann Pharmacother; 2006 Apr; 40(4):704-9. PubMed ID: 16551767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic perspectives for once-daily antiretroviral therapy.
    Anderson PL
    Ann Pharmacother; 2004 Nov; 38(11):1924-34. PubMed ID: 15479772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic complications of human immunodeficiency virus infection: changing epidemiology, treatments, and special considerations in the era of highly active antiretroviral therapy.
    Klibanov OM; Clark-Vetri R
    Pharmacotherapy; 2007 Jan; 27(1):122-36. PubMed ID: 17192166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apricitabine: a nucleoside reverse transcriptase inhibitor for HIV infection.
    Gaffney MM; Belliveau PP; Spooner LM
    Ann Pharmacother; 2009 Oct; 43(10):1676-83. PubMed ID: 19737995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor.
    Modrzejewski KA; Herman RA
    Ann Pharmacother; 2004 Jun; 38(6):1006-14. PubMed ID: 15121999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
    Llibre JM; Domingo P; del Pozo MA; Miralles C; Galindo MJ; Viciana I; Moreno S; Schapiro JM; Clotet B
    J Antimicrob Chemother; 2008 Jan; 61(1):206-9. PubMed ID: 17999972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
    De Clercq E
    Int J Antimicrob Agents; 2009 Apr; 33(4):307-20. PubMed ID: 19108994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M; Verweel G; de Groot R; Burger D
    Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why do patients fail HIV therapy?
    Waters L; Nelson M
    Int J Clin Pract; 2007 Jun; 61(6):983-90. PubMed ID: 17504360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
    Lagnese M; Daar ES
    Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy results of once-daily emtricitabine-based highly active antiretroviral therapy regimens in human immunodeficiency virus-infected pediatric subjects.
    Saez-Llorens X; Violari A; Ndiweni D; Yogev R; Cashat M; Wiznia A; Chittick G; Harris J; Hinkle J; Blum MR; Adda N; Rousseau F;
    Pediatrics; 2008 Apr; 121(4):e827-35. PubMed ID: 18332076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fosamprenavir: drug development for adherence.
    Hester EK; Chandler HV; Sims KM
    Ann Pharmacother; 2006; 40(7-8):1301-10. PubMed ID: 16757678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons.
    Clay PG; Voss LE; Williams C; Daume EC
    Ann Pharmacother; 2008 May; 42(5):670-9. PubMed ID: 18413693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.